Definitive Contract 75A50123C00048
Award Date
9/30/23
Potential Completion Date
7/31/26
Potential Value
$389M
Awardee
Codagenix Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Farmingdale, NY 11735, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of the Army Medical Command awarded a $947,584.12 Small Business Innovation Research (SBIR) Phase II contract to Codagenix Inc., a clinical-stage biotechnology company, to develop a flexible, live tetravalent dengue vaccine. This definitive, firm-fixed-price contract has a completion date of June 14, 2023. Codagenix has also been awarded several other federal contracts and grants for the research, development, and clinical evaluation of viral vaccines, including a $389 million...
This $148,851.02 firm fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the U.S. Army Medical Command (MEDCOM) to Codagenix Inc., a clinical-stage biotechnology company. The contract is for the development of a balanced and efficacious live-attenuated tetravalent dengue vaccine. Codagenix has received additional federal funding, including a $389.4 million contract from the Department of Health and Human Services for a Phase 2B COVID-19 vaccine study and...
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $29.9 million delivery order to Protein Sciences Corporation under the Pandemic Influenza Preparedness and Response 2016-2021 master IDIQ contract. The delivery order is for non-clinical and Phase I clinical studies of a stabilized pre-fusion trimer of the spike protein COVID-19 vaccine candidate reconstituted with two adjuvants, AS03 and AF03, to be performed in Meriden,...
This federal contract award, valued at $7,521,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Protein Sciences Corp, a for-profit manufacturer, to conduct research, development, manufacturing, and testing of vaccine candidates, antigens, proteins, seed lots, and assays to support medical countermeasure preparedness against influenza strains and COVID-19. The award is part of the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for...
This is a $29,400 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Dexorgen Inc., doing business as Codex Biosolutions Inc. Codex Biosolutions is a minority-owned, small disadvantaged business that specializes in advanced biotechnological research, particularly in cell line development, genetic engineering, and translational science support. The contract,...
This contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Auravax Therapeutics, Inc., a for-profit small disadvantaged business. The objective is to assess the ability of Auravax's novel mucosal adjuvant NanoSting-002, together with an influenza live attenuated virus (LAV) created by Codagenix's synthetic attenuated virus engineering technology. The contract is a definitive, firm-fixed-price contract with a ceiling...
This federal contract was awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Codex Biosolutions Inc., a minority-owned small business located in Gaithersburg, Maryland. The $15,100 firm fixed-price purchase order contract is for Codex Biosolutions to provide research and development services, including generating custom cell lines and supplying pseudovirus particles and stable cell lines expressing SARS-CoV-2 variants to...
This is a $1,754,345,480.45 definitive cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Moderna, Inc. for the development of an mRNA vaccine to licensure for the prevention of COVID-19. The contract includes pre-award costs, development of the mRNA vaccine to Biologics License Application (BLA), and domestic manufacturing scale-out. This award does not have a set-aside designation. Moderna, a for-profit pharmaceutical...
This is a federal contract award to Protein Sciences Corp, a for-profit vaccine manufacturer, by the U.S. Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). The $2,146,389.00 firm fixed-price contract is a delivery order under ASPR's Pandemic Influenza Preparedness and Response 2016-2021 master IDIQ contract. The purpose of the award is for Protein Sciences to manufacture 1 bulk lot of an H7 vaccine. No set-aside designation was...
This is a $203.2 million cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Novavax Inc. for the advanced development of recombinant influenza vaccine products and manufacturing capabilities. The contract, which has no set-aside designation, runs through February 2020. Novavax is a biotechnology company that develops and produces recombinant protein nanoparticle vaccines. Through...